Liraglutide Ameliorates Metabolic Dysfunction Targeting the NRF2 Pathway in Obese Rats Induced by a High-Fat Diet
Main Article Content
Abstract
Background: Obesity, driven largely by high-fat diets, is strongly linked to insulin resistance, dyslipidemia, and oxidative stress. The nuclear factor erythroid 2-related factor 2 (NRF2) pathway is very important for keeping the redox balance in cells and guarding against liver damage caused by obesity. Liraglutide, a Glucagon like peptide-1 receptor agonist (GLP-1RA), has demonstrated potential in metabolic control and antioxidant defense.
Objective: This study investigated the dose-dependent effects of liraglutide on weight control, glycemic status, lipid profile, and hepatic NRF2 expression in high-fat diet–induced obese rats.
Methods: Thirty-five male Wistar rats were divided randomly into five groups: control, high-fat diet (HFD), and three liraglutide-treated groups (100, 200, and 400 µg/kg/day, subcutaneously for 28 days following HFD induction). Body weight, Lee index, fasting glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), lipid parameters, and NRF2 (immunohistochemistry) were assessed. Statistical significance was evaluated by ANOVA with Tukey’s post hoc test.
Results: High-fat diet induction caused marked obesity, dyslipidemia, hyperglycemia, hyperinsulinemia, and a sharp reduction in hepatic NRF2 expression. Liraglutide produced clear dose-dependent improvements across all parameters. Body weight and Lee index declined significantly after treatment, with the 400 µg/kg dose nearly restoring normal adiposity. Glycemic indices (glucose, insulin, HOMA-IR) improved progressively, and the highest dose achieved near-normal insulin sensitivity. Lipid abnormalities were corrected, showing increased HDL and reduced LDL, cholesterol, and triglycerides. NRF2 immuno-expression increased markedly in a dose-dependent manner, with the high dose showing the strongest restoration of antioxidant defense.
Conclusion: Liraglutide exerts a strong dose-dependent protective effect against HFD-induced obesity and metabolic dysfunction. Its dual action on glycemic control and NRF2-mediated antioxidant defense highlights its therapeutic potential for managing obesity, insulin resistance, and related hepatic complications.
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
1- Upadhyay J, Farr O, Perakakis N, Ghaly W, Mantzoros C. Obesity as a Disease. Med Clin North Am [Internet]. 2018 Jan 1 [cited 2025 Sept 10];102(1):13–33. Available from: https://www.sciencedirect.com/science/article/pii/S0025712517301281 DOI: https://doi.org/10.1016/j.mcna.2017.08.004
2- Kokkorakis M, Chakhtoura M, Rhayem C, Al Rifai J, Ghezzawi M, Valenzuela-Vallejo L, et al. Emerging pharmacotherapies for obesity: A systematic review. Pharmacol Rev [Internet]. 2025 Jan 1 [cited 2025 Sept 12];77(1):100002. Available from: https://www.sciencedirect.com/science/article/pii/S0031699724000024 DOI: https://doi.org/10.1124/pharmrev.123.001045
3- Friedrich MJ. Global Obesity Epidemic Worsening. JAMA [Internet]. 2017 Aug 15 [cited 2025 Sept 12];318(7):603. Available from: https://doi.org/10.1001/jama.2017.10693 DOI: https://doi.org/10.1001/jama.2017.10693
4- Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism [Internet]. 2019 Mar 1 [cited 2025 Sept 12]; 92:6–10. Available from: https://www.sciencedirect.com/science/article/pii/S002604951830194X DOI: https://doi.org/10.1016/j.metabol.2018.09.005
5- Arif IS, Raoof IB, Luaibi HH. Nuclear Factor Erythroid-2 Linked Factor (Nrf2) as a Potential Mediator of Hepatotoxicity. Al Mustansiriyah J Pharm Sci [Internet]. 2021 [cited 2025 Aug 28];21(4):12–6. Available from: https://ajps.uomustansiriyah.edu.iq/index.php/AJPS/article/view/796
6- Thimmulappa RK, Lee H, Rangasamy T, Reddy SP, Yamamoto M, Kensler TW, et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest [Internet]. 2016 Dec 7 [cited 2025 Sept 26];116(4):984–95. Available from: https://www.jci.org/articles/view/25790 DOI: https://doi.org/10.1172/JCI25790
7- Kobayashi M, Yamamoto M. Nrf2–Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul [Internet]. 2006 Jan 1 [cited 2025 Sept 26];46(1):113–40. Available from: https://www.sciencedirect.com/science/article/pii/S0065257106000094 DOI: https://doi.org/10.1016/j.advenzreg.2006.01.007
8- Blüher M, Aras M, Aronne LJ, Batterham RL, Giorgino F, Ji L, et al. new insights into the treatment of obesity. Diabetes Obes Metab [Internet]. 2023 [cited 2025 Sept 26];25(8):2058–72. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/dom.15077 DOI: https://doi.org/10.1111/dom.15077
9- Croom KF, McCormack PL. Liraglutide. Drugs [Internet]. 2009 Oct 1 [cited 2024 Nov 21];69(14):1985–2004. Available from: https://doi.org/10.2165/11201060-000000000-00000 DOI: https://doi.org/10.2165/11201060-000000000-00000
10- Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean MEJ, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes [Internet]. 2012 June [cited 2024 Nov 21];36(6):843–54. Available from: https://www.nature.com/articles/ijo2011158 DOI: https://doi.org/10.1038/ijo.2011.158
11- Bode B. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract [Internet]. 2012 July 1 [cited 2024 Nov 21];97(1):27–42. Available from: https://www.sciencedirect.com/science/article/pii/S0168822711006978 DOI: https://doi.org/10.1016/j.diabres.2011.12.015
12- Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med [Internet]. 2015 July 2 [cited 2024 Nov 21];373(1):11–22. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1411892 DOI: https://doi.org/10.1056/NEJMoa1411892
13- Kurkin DV, Bakulin DA, Morkovin EI, Petrov VI, Strygin AV, Koryanova KN, et al. Physiology and pharmacology of glucagon-like peptide-1 receptor. Pharm Pharmacol [Internet]. 2024 Jan 9 [cited 2025 Sept 26];11(4):347–80. Available from: https://www.pharmpharm.ru/jour/article/view/1386 DOI: https://doi.org/10.19163/2307-9266-2023-11-4-347-380
14- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab [Internet]. 2018 Apr 3 [cited 2024 Nov 20];27(4):740–56. Available from: https://www.cell.com/cell-metabolism/abstract/S1550-4131(18)30179-7 DOI: https://doi.org/10.1016/j.cmet.2018.03.001
15- Magdy YM, El-Kharashi OA, Nabih ES, Shaker SM, Abd-Elaziz LF, Aboul-Fotouh S. Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress. Biomed Pharmacother [Internet]. 2017 Jan 1 [cited 2025 June 20]; 85:225–38. Available from: https://www.sciencedirect.com/science/article/pii/S0753332216315918 DOI: https://doi.org/10.1016/j.biopha.2016.10.098
16- Ekeleme CM, Odey DO, Ibeneme CE, David-Oku E, Eyong EU, Atangwho IJ, et al. Ameliorative potentials of ethanol extract of Alchornea cordifolia on some biochemical and physiological parameters in high-fat diet-induced obese Wistar rats [Internet]. In Review; 2024 [cited 2025 June 20]. Available from: https://www.researchsquare.com/article/rs-4100421/v1 DOI: https://doi.org/10.21203/rs.3.rs-4100421/v1
17- Palleria C, Leo A, Andreozzi F, Citraro R, Iannone M, Spiga R, et al. Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects. Behav Brain Res [Internet]. 2017 Mar 15 [cited 2025 June 20];321:157–69. Available from: https://www.sciencedirect.com/science/article/pii/S0166432816310701 DOI: https://doi.org/10.1016/j.bbr.2017.01.004
18- He Y, Ao N, Yang J, Wang X, Jin S, Du J. The preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy. Ann Hepatol [Internet]. 2020 Jan [cited 2025 Nov 12];19(1):44–52. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1665268119322355 DOI: https://doi.org/10.1016/j.aohep.2019.06.023
19- Liraglutide Attenuates Myocardial Fibrosis via Inhibition of AT1R-Mediated ROS Production in Hypertensive Mice [Internet]. [cited 2025 Nov 12]. Available from: https://journals.sagepub.com/doi/epdf/10.1177/1074248420942007?src=getftr&utm_source=mendeley&getft_integrator=mendeley
20- Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J Pharmacol Pharmacother [Internet]. 2010 [cited 2025 Aug 4];1(2):87–93. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043327/ DOI: https://doi.org/10.4103/0976-500X.72350
21- TKBSIS48_CHOLESTEROL-LQ_2019.pdf [Internet]. [cited 2025 Sept 26]. Available from: https://www.spinreact.com/assets/files/Inserts/SERIE_SPINTECH_(TKB)/Bioquimica/TKBSIS48_CHOLESTEROL-LQ_2019.pdf
22- MDBSIS49_TG_LIQ_2020.pdf [Internet]. [cited 2025 Sept 26]. Available from: https://www.spinreact.com/files/Inserts/MD/BIOQUIMICA/MDBSIS49_TG_LIQ_2020.pdf
23- TKBSIS37_HDLc-D_2019.pdf [Internet]. [cited 2025 Sept 26]. Available from: https://www.spinreact.com/assets/files/Inserts/SERIE_SPINTECH_(TKB)/Bioquimica/TKBSIS37_HDLc-D_2019.pdf
24- tkbsis46_glucose-lq-2019.pdf [Internet]. [cited 2025 Sept 26]. Available from: https://www.spinreact.com/assets/files/Inserts/SERIE_SPINTECH_(TKB)/Bioquimica/tkbsis46_glucose-lq-2019.pdf
25- Hata Y, Nakajima K. Application of Friedewald’s Ldl-Cholesterol Estimation Formula to Serum Lipids in the Japanese Population. Jpn Circ J. 1986;50(12):1191–200. DOI: https://doi.org/10.1253/jcj.50.1191
26- ELISA Kit for Insulin (INS) [Internet]. [cited 2025 Sept 28]. Available from: https://www.cloud-clone.com/manual/ELISA-Kit-for-Insulin-(INS)-CEA448Hu.pdf
27- Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract [Internet]. 2017 [cited 2025 Sept 12];3(1):3–14. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/osp4.84 DOI: https://doi.org/10.1002/osp4.84
28- Inc NN. Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management [Internet]. [cited 2025 Sept 12]. Available from: https://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-for-saxenda-liraglutide-rdna-origin-injection-for-chronic-weight-management-300013975.html
29- Buettner R, Schölmerich J, Bollheimer LC. High-fat Diets: Modeling the Metabolic Disorders of Human Obesity in Rodents. Obesity [Internet]. 2007 [cited 2025 July 18];15(4):798–808. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1038/oby.2007.608 DOI: https://doi.org/10.1038/oby.2007.608
30- Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest [Internet]. 2017 May 5 [cited 2025 July 25];114(12):1752–61. Available from: https://www.jci.org/articles/view/21625 DOI: https://doi.org/10.1172/JCI21625
31- Arif IS, Raoof IB, Luaibi HH. Nuclear Factor Erythroid-2 Linked Factor (Nrf2) as a Potential Mediator of Hepatotoxicity. Al Mustansiriyah J Pharm Sci [Internet]. 2021 [cited 2025 Oct 1];21(4):12–6. Available from: https://ajps.uomustansiriyah.edu.iq/index.php/AJPS/article/view/796 DOI: https://doi.org/10.32947/ajps.v21i4.796
32- Dodson M, Castro-Portuguez R, Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol [Internet]. 2019 May 1 [cited 2024 Nov 15]; 23:101107. Available from: https://www.sciencedirect.com/science/article/pii/S2213231718310267 DOI: https://doi.org/10.1016/j.redox.2019.101107
33- Liraglutide Impacts Iron Homeostasis in a Murine Model of Hereditary Hemochromatosis | Endocrinology | Oxford Academic [Internet]. [cited 2025 Aug 1]. Available from: https://academic.oup.com/endo/article/165/9/bqae090/7718935 DOI: https://doi.org/10.1210/endocr/bqae090